In a major development, Cohance Lifesciences has roped in Umang Vohra as its Chairman and Group CEO. Formerly of Cipla, Vohra is one of India's most recognised faces in the pharmaceutical sector and will look to steer the contract development and manufacturing organisation (CDMO) through its next phase of growth.
Vohra served as Managing Director and Global CEO of Cipla from 2016 to March 31, 2026. During his time at Cipla, he played a key role in repositioning the company from a volume-driven generics manufacturer to a high-value pharma player.
Under his leadership, Cipla pivoted away from commodity generics toward complex and specialty products, building scale in respiratory and chronic therapies with a focus on high-barrier, differentiated portfolios.
The move paid off as well, with Cipla becoming the world's largest inhaler seller by volume, ranking among the top players in the US inhalation generics and established global leadership in respiratory care at industrial scale.
That track record makes Vohra a particularly strategic fit for Cohance, which is itself navigating a similar transition, from volume manufacturing toward value-based partnerships with innovator and specialty pharma clients.
Vohra's appointment could go a long way in addressing several of Cohance's core priorities. On the scaling side, he brings proven track record of driving global growth while protecting margins, which is often a critical balance to have for CDMOs operatin gin a competitive and capital intensive environment.
In terms of culture, his customer-centric CDMO mindset aligns with Cohance's ambition to deepen long-term client partnerships rather than chase transactional volumes.
On governance, Vohra is expected to support the company's transition to a more professionally managed, institution-led structure.
And on capital markets, his track record is seen as enhancing investor confidence at a time when Cohance is seeking greater strategic clarity and credibility with institutional stakeholders. In fact, investors have already welcomed the appointment with open arms, with shares of Cohance hitting the upper circuit in trade on Monday.
ALSO READ: Paytm Shares Tumble 8% After RBI Ban On Payments Bank Unit
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
